Post-earnings recap
Reported
Fri, Mar 10, 2017
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
25%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
TG Therapeutics reported a larger-than-expected loss per share, which contributed to a 3.39% decline in stock price following the earnings announcement. The absence of revenue figures and forward guidance may raise concerns among investors about the company's near-term prospects. The market reaction reflects uncertainty regarding the company's future performance and strategic direction.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.48 | N/A | -24.68% |
| Revenue | N/A | N/A | N/A |
Management expressed a cautious approach due to the lack of specific guidance. They emphasized their commitment to ongoing clinical development.
Management did not provide specific guidance for future quarters.
The company is focused on advancing its clinical programs.